ReviewProstate cancer and prostatic diseases2003
Models of metastatic prostate cancer: a transgenic perspective.
Review in Prostate cancer and prostatic diseases, 2003. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
21 citing papers in PubMed.
- Dimethylaminomicheliolide Sensitizes Cancer Cells to Radiotherapy for Synergistic Combination with Immune Checkpoint Blockade.Advanced therapeutics · 2022Article
- Establishment and characterization of stable red, far-red (fR) and near infra-red (NIR) transfected canine prostate cancer cell lines.Cancer cell international · 2020Article
- Specific expression pattern of tissue cytokines analyzed through the Surface Acoustic Wave technique is associated with age-related spontaneous benign prostatic hyperplasia in rats.Biochemistry and biophysics reports · 2018Article
- Glipizide suppresses prostate cancer progression in the TRAMP model by inhibiting angiogenesis.Scientific reports · 2016Article
- Mouse models for studying prostate cancer bone metastasis.BoneKEy reports · 2016Article
- Current mouse and cell models in prostate cancer research.Endocrine-related cancer · 2013Review
- In vivo animal models for studying brain metastasis: value and limitations.Clinical & experimental metastasis · 2013Review
- Targeting and killing of metastatic cells in the transgenic adenocarcinoma of mouse prostate model with vesicular stomatitis virus.Molecular therapy : the journal of the American Society of Gene Therapy · 2013Article
- Preclinical Remodeling of Human Prostate Cancer through the PTEN/AKT Pathway.Advances in urology · 2012Article
- Conditional expression of the androgen receptor induces oncogenic transformation of the mouse prostate.The Journal of biological chemistry · 2011Article
- Mouse models of prostate cancer.Prostate cancer · 2011Article
- Survivin is a potential mediator of prostate cancer metastasis.International journal of radiation oncology, biology, physics · 2010Article
- Molecular genetics of prostate cancer: new prospects for old challenges.Genes & development · 2010Review
- Early and delayed castrations confer a similar survival advantage in TRAMP mice.Asian journal of andrology · 2009Article
- Effects of castration on the development of prostate adenocarcinoma from its precursor HGPIN and on the occurrence of androgen-independent, poorly differentiated carcinoma in TRAMP mice.Prostate cancer and prostatic diseases · 2008Article
- Article
- Tumor cell transendothelial passage in the absorbing lymphatic vessel of transgenic adenocarcinoma mouse prostate.The American journal of pathology · 2007Article
- Application of Gleason analogous grading system and flow cytometry DNA analysis in a novel knock-in mouse prostate cancer model.Postgraduate medical journal · 2006Article
- Article
- Assessing tumor growth and distribution in a model of prostate cancer metastasis using bioluminescence imaging.Clinical & experimental metastasis · 2005Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeTransgenic mouse models are proving to be invaluable in our effort to understand the molecular basis of metastatic prostate cancer (CaP). We review and discuss how current animal models have contributed to our understanding of the metastatic cascade and how transgenic technology is being used to develop the next generation of mouse models. Our goal is to provide a review of the recent advances and provide a framework for further studies. MATERIALS AND
methodsWe performed a MEDLINE search of the literature on CaP metastasis transgenic and animal models.
resultsWe present a summary of the characteristics of nine different animal models of CaP. Each model is unique and provides valuable insight into the molecular mechanisms governing the progression of CaP. Our experience with transgenic models and all the new data from the literature predicts that we will be able to develop genetically engineered mice that accurately mimic the heterogeneity, androgen-independent growth, and metastatic spread seen in clinical disease.
conclusionIn order to elucidate the molecular mechanisms of CaP metastasis, it will be necessary to compare gene and protein expression patterns and biochemical analyses of clinical metastatic disease with data obtained from current models. We will also need to refine our ability to engineer and characterize genetic perturbation models. This type of integrative and iterative approach should facilitate better understanding of the molecular biology of CaP metastases.
Indexed as
Identifiers
12970722What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.